Takuro Kometani

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation

Mayumi Ono, Akira Hirata, Takuro Kometani et al. · Molecular Cancer Therapeutics · 2004 · 308 citations · Full text

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

Akira Hirata, S. Ogawa, Takuro Kometani et al. · PubMed · 2002 · 259 citations

Never‐smoking nonsmall cell lung cancer as a separate entity

Tokujiro Yano, Naoko Miura, Tomoyoshi Takenaka et al. · Cancer · 2008 · 143 citations

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

Takashi Seto, Taito Esaki, Fumihiko Hirai et al. · Cancer Chemotherapy and Pharmacology · 2013 · 101 citations

Dose-escalation Study, Radiation Medicine, Medicine +10

Induction of epithelial‐mesenchymal transition‐related genes by benzo[a]pyrene in lung cancer cells

Ichiro Yoshino, Takuro Kometani, Fumihiro Shoji et al. · Cancer · 2007 · 81 citations